Dopamine Dysfunction in Schizophrenia

Dopamine Handbook

Volumn , Issue , 2010, Pages

  Abi Dargham, Anissa ^a   Slifstein, Mark ^a   Kegeles, Larry ^a   Laruelle, Marc ^b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Dopamine; Dopamonergic system; Dysregulation; Schizophrenia; Striatum

Indexed keywords

EID: 84864591540     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780195373035.003.0036     Document Type: Chapter

References (80)

1. Weinberger DR. Implications of the normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987;44:660-669.
2. Goldman-Rakic P. Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci. 1994;6(4):348-357.
3. Goldman-Rakic PS, Muly EC 3rd, Williams GV. D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev. 2000;31(2-3):295-301.
4. Goldberg TE, Weinberger DR. Genes and the parsing of cognitive processes. Trends Cogn Sci. 2004;8(7):325-335.
5. Weinberger DR, Berman KF, Chase TN. Mesocortical dopaminergic function and human cognition. Ann NY Acad Sci. 1988;537:330-338.
6. Akil M, Edgar CL, Pierri JN, Casali S, Lewis DA. Decreased density of tyrosine hydroxylase-immunoreactive axons in the entorhinal cortex of schizophrenic subjects. Biol Psychiatry. 2000;47(5):361-370.
7. Okubo Y, Suhara T, Suzuki K, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature. 1997;385(6617):634-636.
8. Karlsson P, Farde L, Halldin C, Sedvall G. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry. 2002;159(5):761-767.
9. Abi-Dargham A, Mawlawi O, Lombardo I, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci. 2002;22(9):3708-3719.
10. Guo, N. N., D. R. Hwang, et al. (2003). "Dopamine depletion and in vivo binding of PET D-1 receptor radioligands: Implications for imaging studies in schizophrenia." Neuropsychopharmacology 28(9):1703-1711.
11. Dumartin B, Jaber M, Gonon F, Caron MG, Giros B, Bloch B. Dopamine tone regulates D1 receptor trafficking and delivery in striatal neurons in dopamine transporter-deficient mice. Proc Natl Acad Sci USA. 2000;97(4):1879-1884.
12. Scott L, Kruse MS, Forssberg H, Brismar H, Greengard P, Aperia A. Selective up-regulation of dopamine D1 receptors in dendritic spines by NMDA receptor activation. Proc Natl Acad Sci USA. 2002;99(3):1661-1664.
13. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab. 2000;20(3):423-451.
14. Narendran R, Frankle WG, Keefe R, et al. Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am J Psychiatry. 2005;162(12):2352-2359.
15. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1999;20(3):201-225.
16. Jentsch JD, Redmond DE Jr, Elsworth JD, Taylor JR, Youngren KD, Roth RH. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science. 1997;277(5328):953-955.
17. Kakiuchi T, Nishiyama S, Sato K, Ohba H, Nakanishi S, Tsukada H. Effect of MK801 on dopamine parameters in the monkey brain. Neuroimage. 2001;16:110P.
18. Tsukada H, Nishiyama S, Fukumoto D, Sato K, Kakiuchi T, Domino EF. Chronic NMDA antagonism impairs working memory, decreases extracellular dopamine, and increases D1 receptor binding in prefrontal cortex of conscious monkeys. Neuropsychopharmacology. 2005;30(10):1861-1869.
19. Slifstein M, Kolachana B, Simpson EH, et al. COMT genotype predicts cortical-limbic D1 receptor availability measured with [(11)C]NNC112 and PET. Mol Psychiatry. 2008;13(8):821-827.
20. George MS, Molnar CE, Grenesko EL, et al. A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res. 2007;93(1-3):42-50.
21. Castner SA, Williams GV, Goldman-Rakic PS. Reversal of antipsychoticinduced working memory deficits by short-term dopamine D1 receptor stimulation. Science. 2000;287(5460): 2020-2022.
22. Castner SA, Goldman-Rakic PS. Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation. J Neurosci. 2004;24(6):1446-1450.
23. Flores-Hernandez J, Cepeda C, Hernandez-Echeagaray E, et al. Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32. J Neurophysiol. 2002;88(6):3010-3020.
24. Dunah AW, Standaert DG. Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J Neurosci. 2001;21(15):5546-5558.
25. Narendran, R., W. G. Frankle, et al. "Positron Emission Tomography Imaging of Amphetamine-Induced Dopamine Release in the Human Cortex: A Comparative Evaluation of the High Affinity Dopamine D-2/3 Radiotracers [C-11]FLB 457 and [C-11]Fallypride." Synapse 2009 63(6):447-461.
26. Kegeles L, Frankle W, Gil R, et al. Schizophrenia is associated with increased synaptic dopamine in associative rather than limbic regions of the striatum: implications for mechanisms of action of antipsychotic drugs. J Nucl Med. 2006(47):139P.
27. Howes OD, Montgomery AJ, Asselin MC, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009;66(1):13-20.
28. Weinberger D, Laruelle M. Neurochemical and neuropharmachological imaging in schizophrenia. In: Davis KL, Charney DS, Coyle J, Nemeroff C, eds. Neuropsychopharmacology-The Fifth Generation of Progress: Lippincott Williams and Wilkins; 2001:Philadelphia, PA, 833-855.
29. Dao-Castellana MH, Paillere-Martinot ML, Hantraye P, et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res. 1997;23(2):167-174.
30. Elkashef AM, Doudet D, Bryant T, Cohen RM, Li SH, Wyatt RJ. 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res. 2000;100(1): 1-11.
31. Hietala J, Syvalahti E, Vilkman H, et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res. 1999;35(1):41-50.
32. Hietala J, Syvalahti E, Vuorio K, et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet. 1995;346(8983):1130-1131.
33. Lindstrom LH, Gefvert O, Hagberg G, et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry. 1999;46(5):681-688.
34. McGowan S, Lawrence AD, Sales T, Quested D, Grasby P. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry. 2004;61(2):134-142.
35. Meyer-Lindenberg A, Miletich RS, Kohn PD, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci. 2002;5(3):267-271.
36. Reith J, Benkelfat C, Sherwin A, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA. 1994;91(24):11651-11654.
37. Grunder G, Vernaleken I, Muller MJ, et al. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology. 2003;28(4):787-794.
38. Laruelle M, Abi-Dargham A, van Dyck CH, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA. 1996;93(17):9235-9240.
39. Abi-Dargham A, Gil R, Krystal J, et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry. 1998;155(6):761-767.
40. Breier A, Su TP, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA. 1997;94(6):2569-2574.
41. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry. 1999;46(1):56-72.
42. Abi-Dargham A, Kegeles L, Zea-Ponce Y, et al. Amphetamine-induced dopamine release in patients with schizotypal personality disorders studied by SPECT and [123I]IBZM. Biological psychiatry 2004 55(10): 1001-1006.
43. Parsey RV, Oquendo MA, Zea-Ponce Y, et al. Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry. 2001;50(5):313-322.
44. Abi-Dargham A, Rodenhiser J, Printz D, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA. 2000;97(14):8104-8109.
45. Kegeles L, Frankle W, Gil R, et al. Schizophrenia is associated with increased synaptic dopamine in associative rather than limbic regions of the striatum: implications for mechanisms of action of antipsychotic drugs. J Nucl Med. 2006(47):139P.
46. Graff-Guerrero A, Mizrahi R, Agid O, et al. The dopamine D(2) receptors in high-affinity state and D(3) receptors in schizophrenia: a clinical [(11)C]-(+)-PHNO PET study. Neuropsycho-pharmacology. 2008; 34(4):1078-1086.
47. Haber SN, Fudge JL, McFarland NR. Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. J Neurosci. 2000;20(6):2369-2382.
48. Haber SN, McFarland NR. The concept of the ventral striatum in nonhuman primates. Ann NY Acad Sci. 1999;877:33-48.
49. Haber SN, Ryoo H, Cox C, Lu W. Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. J Comp Neurol. 1995;362(3):400-410.
50. Tuppurainen H, Kuikka J, Viinamaki H, Husso-Saastamoinen M, Bergstrom K, Tiihonen J. Extrastriatal dopamine D2/3 receptor density and distribution in drug-naive schizophrenic patients. Mol Psychiatry. 2003;8(4):453-455.
51. Talvik M, Nordstrom AL, Olsson H, Halldin C, Farde L. Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with schizophrenia: a PET study with [11C]FLB 457. Int J Neuropsychopharmacol. 2003;6(4):361-370.
52. Talvik M, Nordstrom AL, Okubo Y, et al. Dopamine D2 receptor binding in drug-naive patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res. 2006;148(2-3):165-173.
53. Yasuno F, Suhara T, Okubo Y, et al. Low dopamine D(2) receptor binding in subregions of the thalamus in schizophrenia. Am J Psychiatry. 2004;161(6):1016-1022.
54. Suhara T, Okubo Y, Yasuno F, et al. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry. 2002;59(1):25-30.
55. Tuppurainen H, Kuikka JT, Laakso MP, Viinamaki H, Husso M, Tiihonen J. Midbrain dopamine D2/3 receptor binding in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2006;256(6): 382-387.
56. Glenthoj BY, Mackeprang T, Svarer C, et al. Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biol Psychiatry. 2006;60(6):621-629.
57. Kessler, R., N. Woodward, et al. Dopamine D2 Receptor Levels in Striatum, Thalamus, Substantia Nigra, Limbic Regions, and Cortex in Schizophrenic Subjects. Biological psychiatry 2009 65(12): 1024-1031.
58. Kegeles LS, Slifstein M, Xu X, Hackett E, Castrillon J, Bae S-A, Urban N, Laruelle M, Abi-Dargham A: [18F]Fallypride PET (p.519) assessment of D2/D3 receptor binding in schizophrenia. J Nucl Med 2008;49:36P.
59. Haber SN, Kim KS, Mailly P, Calzavara R. Reward-related cortical inputs define a large striatal region in primates that interface with associative cortical connections, providing a substrate for incentive-based learning. J Neurosci. 2006;26(32): 8368-8376.
60. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience. 1991;41(1):1-24.
61. Abi-Dargham A, Van de Giessen E, Slifstein M, Kegeles L, Laruelle M. "Baseline and Amphetamine-Stimulated Dopamine Activity Are Related in Drug-Naïve Schizophrenic Subjects." Biological psychiatry 2009 65(12):1091-1093.
62. Chrapusta SJ, Egan MF, Wyatt RJ, Weinberger DR, Lipska BK. Neonatal ventral hippocampal damage modifies serum corticosterone and dopamine release responses to acute footshock in adult Sprague-Dawley rats. Synapse. 2003;47(4):270-277.
63. Lodge DJ, Grace AA. Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J Neurosci. 2007;27(42):11424-11430.
64. Moore H, Jentsch JD, Ghajarnia M, Geyer MA, Grace AA. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry. 2006;60(3): 253-264.
65. Ozawa K, Hashimoto K, Kishimoto T, Shimizu E, Ishikura H, Iyo M. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry. 2006;59(6):546-554.
66. Pycock CJ, Kerwin RW, Carter CJ. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature. 1980;286:74-77.
67. Bubser M, Koch M. Prepulse inhibition of the acoustic startle response of rats is reduced by 6-hydroxydopamine lesions of the medial prefrontal cortex. Psychopharmacology. 1994;113 (3-4):487-492.
68. Deutch A, Clark WA, Roth RH. Prefrontal cortical dopamine depletion enhances the responsiveness of the mesolimbic dopamine neurons to stress. Brain Res. 1990;521:311-315.
69. Thompson TL, Moss RL. In vivo stimulated dopamine release in the nucleus accumbens: modulation by the prefrontal cortex. Brain Res. 1995;686(1):93-98.
70. Roberts AC, Desalvia MA, Wilkinson LS, et al. 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin card sort test: possible interactions with subcortical dopamine. J. Neurosci. 1994;14(5 pt 1):2531-2544.
71. Kolachana BS, Saunders R, Weinberger D. Augmentation of prefrontal cortical monoaminergic activity inhibits dopamine release in the caudate nucleus: an in vivo neurochemical assessment in the rhesus monkey. Neuroscience. 1995;69:859-868.
72. Karreman M, Moghaddam B. The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: an effect mediated by ventral tegmental area. J Neurochem. 1996;66:589-598.
73. Tzschentke TM. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog Neurobiol. 2001;63(3):241-320.
74. Kellendonk C, Simpson EH, Polan HJ, et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron. 2006;49(4):603-615.
75. Konradi C. The molecular basis of dopamine and glutamate interactions in the striatum. Adv Pharmacol. 1998;42:729-733.
76. Leveque JC, Macias W, Rajadhyaksha A, et al. Intracellular modulation of NMDA receptor function by antipsychotic drugs. J Neurosci. 2000;20(11):4011-4020.
77. Krystal JH, D'Souza DC, Gallinat J, et al. The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia. Neurotox Res. 2006;10(3-4):235-252.
78. Heckers S, Rauch SL, Goff D, et al. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat Neurosci. 1998;1(4):318-323.
79. Medoff DR, Holcomb HH, Lahti AC, Tamminga CA. Probing the human hippocampus using rCBF: contrasts in schizophrenia. Hippocampus. 2001;11(5):543-550.
80. Meyer-Lindenberg AS, Olsen RK, Kohn PD, et al. Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia. Arch Gen Psychiatry. 2005;62(4):379-386.